Overview

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Status:
Terminated

Trial end date:
2021-04-05

Target enrollment:

Participant gender:

Summary

This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in patients with presumed Nonalcoholic Steatohepatitis (NASH).

Phase:

Phase 2

Details

Lead Sponsor:

Corcept Therapeutics

Treatments:

Cortisone
Cortisone acetate